What partners of the Inflammatory Markers for Early Detection and Subtyping of Neurodegenerative and Mood Disorders Project are saying...

Alzheimer’s Drug Discovery Foundation

“Research on inflammatory mechanisms in Alzheimer’s disease, including our own, dates back to the early 1980s. Indeed, Dr. Alzheimer describes microglia surrounding the senile plagues in 1906,” said Howard Fillit, M.D., Founding Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation. “It is therefore timely that modern clinical trials, and the associated development of validated inflammatory biomarkers, has come of age and entered the mainstream of therapeutic development for new drugs for Alzheimer’s disease.”

Foundation for the National Institutes of Health

“The FNIH Biomarkers Consortium brings together the expertise and resources of government, industry and not-for-profit partners to uncover critical signals of disease that can accelerate therapy development for patients around the world,” said Joe Menetski, Ph.D., Associate Vice President of Research Partnerships, Foundation for the National Institutes of Health. “This new Inflammatory Markers project is an exciting opportunity for us to identify a precise combination of biomarkers that can radically improve the way we diagnose and treat patients with neurodegenerative and psychiatric disorders.”

National Institute of Mental Health (NIMH)

“Clarifying the role of inflammation in neuropsychiatric disease would resolve long-standing issues in the field. This effort to develop and characterize biomarkers of neuron inflammation is a crucial step towards this goal,” said Joshua Gordon, M.D., Ph.D., Director of the National Institute of Mental Health (NIMH).